Migraine and the New Anti-CGRP Treatments: Facebook Live with Dr. David Dodick

In September 2018, fremanezumab (AJOVY™), was approved by the FDA for the treatment and prevention of migraine. The news came four months after the FDA approved the first monoclonal antibody, erenumab (Aimovig™), the first treatment specifically designed to prevent migraine. Clinical trials found both treatments to be effective at reducing headache frequency and also found them to be well tolerated. During a recent Facebook Live, Dr. David Dodick, Chair of the American Migraine Foundation and Professor of Neurology at the Mayo Clinic Arizona, discussed the latest CGRP advancements with the migraine community.